Genetics of breast cancer

Drugs of Today

Volumn 40, Issue 12, 2004, Pages 991-1002

  Ingvarsson, Sigurdur ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DNA; PROTEIN P53;

AUTOSOMAL DOMINANT DISORDER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GENETICS; CANCER THERAPY; CELL CYCLE; DNA REPAIR; FAMILIAL CANCER; GENE AMPLIFICATION; GENETIC DISORDER; GENOMIC INSTABILITY; GERM LINE; GERM LINE MUTATION; HUMAN; MUTATION; ONCOGENE; REVIEW; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; GENOMIC INSTABILITY; HUMANS;

EID: 12344272908     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.12.872574     Document Type: Review

References (79)

1. Ingvarsson, S. Molecular genetics of breast cancer progression. Sem Cancer Biol 1999, 9: 277-88.
2. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344: 783-92.
3. Yu, Q.Y., Geng, Y., Sicinski, P. Specific protection against breast cancer by cyclin D1 ablation. Nature 2001, 411: 1017-21.
4. Miki, Y., Swensen, J., Shattuck-Eidens, D. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266: 66-71.
5. Wooster, R., Bignell, G., Lancaster, J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378: 789-92.
6. Ford, D., Easton, D.F., Stratton, M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998, 62: 676-89.
7. King, M.C., Marks, J.H., Mandell, J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302: 643-6.
8. Antoniou, A., Pharoah, P.D.P., Narod, S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003, 72: 1117-30.
9. Johannesdottir, G., Gudmundsson, G., Bergthorsson, J. T. et al. High prevalance of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996, 56: 3663-5.
10. Thorlacius, S., Struewing, J.P., Hartge, P. et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998, 352: 1337-9.
11. Tulinius, H., Olafsdottir, G.H., Sigvaldason, H. et al. The effects of a single BRCA2 mutation on cancer in Iceland. J Med Genet 2002, 39: 457-62.
12. Tryggvadottir, L., Olafsdottir, E.J., Gudlaugsdottir, S. et al. BRCA2 mutation carriers, reproductive factors and breast cancer risk. Breast Cancer Res 2003, 5: R121.
13. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., Holt, J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast-cancer progression. Nature Genet 1995, 9: 444-50.
14. Wilson, C.A., Ramos, L., Villasenor, M.R. et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genet 1999, 21: 236-40.
15. Catteau, A., Harris, W.H., Xu, C.R, Solomon, E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: Correlation with disease characteristics. Oncogene 1999, 18: 1957-65.
16. Dobrovic, A., Simptendorfer, D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997, 57: 3347-50.
17. Rice, U.C., Massey-Brown, K.S., Futscher, B.W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998, 17: 1807-12.
18. Hughes-Davies, L., Huntsman, D., Ruas, M. et al. EMSV links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003, 115: 523-35.
19. Borg, A. Molecular and pathological characterization of inherited breast cancer. Sem Cancer Biol 2001, 11: 375-85.
20. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997, 349: 1505-10.
21. Marcus, J.N., Watson, P., Page, D.L. et al. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996, 77: 697-709.
22. Johannsson, O.T., Idvall, I., Anderson, C. et al. Tumor biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997, 33: 362-71.
23. Ingvarsson, S., Geirsdottir, E.K., Johannesdottir, G. et al. High incidence of loss of heterozygosity in breast tumors from carriers of the 999del5 BRCA2 mutation. Cancer Res 1998, 58: 4421-5.
24. Tirkkonen, M., Johannsson, O., Agnarsson, B.A. et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997, 57: 1222-7.
25. Hedenfalk, I., Duggan, D., Chen, Y. Gene-expression profiles in hereditary breast cancer. Adv Anat Pathol 2002, 9: 1-4.
26. Brodie, S.G., Xu, X.L., Qiao, W.H., Li, W.M., Cao, L., Deng, C.X. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 2001, 20: 7514-23.
27. Hirao, A., Cheung, A., Duncan, G. et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002, 22: 6521-32.
28. Takai, H., Naka, K., Okada, Y. et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002, 21: 5195-205.
29. Scott, D., Spreadborough, A.R., Roberts, S.A. Radiation-induced G2 delay and spontaneous chromosome aberrations in ataxia-telangiectasia homozygotes and heterozygotes. Int J Radiat Biol 1994, 66: 157-63.
30. Swift, M., Morrell, D., Massey, R.B., Chase, C.L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Eng J Med 1991, 325: 1831-6.
31. Scott, S.P., Bendix, R., Chen, P., Clark, R., Dork, T., Lavin, M.F. Missence mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 2002, 99: 925-30.
32. Sommer, S.S., Jiang, Z., Feng, J. et al. ATM missence mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet 2003, 145: 115-20.
33. Olivier, M., Hainaut, P. TP53 mutation pattern in breast cancers: Searching for clues of environmental carcinogenesis. Sem Cancer Biol 2001, 11: 353-60.
34. Malkin, D., Li, F.P., Strong, L.C. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250: 1233-8.
35. Srivastava, S., Zhou, Z.Q., Pirollo, K., Blattner, W., Chang, E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348: 747-9.
36. Borresen, A.L., Andersen, T.I., Eyfjord, U.E. et al. TP53 mutations and breast-cancer prognosis - particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chrom Cancer 1995, 14: 71-5.
37. Bell, D., Varley, J.M., Szydlo, T.E. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286: 2528-31.
38. Ingvarsson, S., Sigbjornsdottir, B.I., Huiping, C. et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 2002, 4: R4.
39. Meijers-Heijboer, H., Van Den Ouweland, A., Klijn, J. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)110OdelC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 2002, 31: 55-9.
40. Meijers-Heijboer, H., Wijnen, J., Vasen, H. et al. The CHEK 11000delC mutation identifies families with a hereditary breast and colorectal phenotype. Am J Hum Genet 2003, 72: 1308-14.
41. Vahteristo, P., Bartkova, J., Eerola, H. et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71: 432-8.
42. Sullivan, A., Yuille, M., Repellin, C. et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 202, 21: 1316-24.
43. Crook, T., Crossland, S., Crompton, M.R., Osin, P., Gusterson, B.A. P53 mutations in BRCA1-associated familial breast cancer. Lancet 1997, 350: 638-9.
44. Crook, T., Brooks, L.A., Crossland, S. et al. p53 mutation with frequent novel codons but not a mutation phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 1998, 17: 1681-9.
45. Greenblatt, M.S., Chappuis, P.O., Bond, J.P., Hamel, N., Foulkes, W.D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations. Cancer Res 2001, 61: 4092-7.
46. Eiriksdottir, G., Barkardottir, R.B., Agnarsson, B.A. et al. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene 1998, 16: 21-6.
47. Gretarsdottir, S., Thorlacius, S., Valgardsdottir, R. et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998, 58: 859-62.
48. Ingvarsson, S. FHIT alterations in breast cancer. Sem Cancer Biol 2001, 11: 361-6.
49. Ingvarsson, S., Agnarsson, B.A., Sigbjornsdottir, B.I. et al. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 1999, 59: 2682-9.
50. Gudmundsson, J., Johannesdottir, G., Bergthorsson, J.T. et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995, 55: 4830-2.
51. Smith, S.A., Easton, D.F., Evans, D.G., Ponder, B.A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 1992, 2: 128-31.
52. Sard, L., Accornero, P., Tornielli, S. et al. The tumor-suppressor gene FHIT is involved in the regulation ofapoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999, 96: 8489-92.
53. Lee, H., Trainer, A.H., Friedman, L.S. et al. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Molec Cell 1999, 4: 1-10.
54. Lee, H. Impaired phosphorylation and mis-localization of Bub1 and BubR1 are responsible for the defective mitotic checkpoint function in Brca2-mutant thymic lymphoma. Exp Mol Med 2003, 35: 448-53.
55. Johnstone, R.W., Ruefli, A.A., Lowe, S.W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002, 108: 153-64.
56. Schmitt, C.A., Fridman, J.S., Yang, M. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109: 335-46.
57. Issaeva, N., Friedler, A., Bozko, P., Wiman, K.G., Fersht, A.R., Selivanova, G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 2003, 100: 13303-7.
58. Chen, H.P., Johannsdottir, J.T., Arason, A. et al. Replication error in human breast cancer: Comparison with clinical variables and family history of cancer. Oncol Rep 1999, 6: 117-22.
59. Adem, C., Soderberg, C.L., Cunningham, J.M. et al. Microsatellite instability in hereditary and sporadic breast cancer. Int J Cancer 2003, 107: 580-2.
60. Eiriksdottir, G., Bergthorsson, J.T., Sigurdsson, H. et al. Mapping of chromosome 3 alterations in human breast cancer using microsatellite PCR markers: Correlation with clinical variables. Int J Oncology 1995, 6: 369-75.
61. Bragadottir, G., Eiriksdottir, G., Sigurdsson, A. et al. Loss of heterozygosity at chromosome 6q correlates with tumor progression and patient survival. Int J Oncol 1995, 7: 871-6.
62. Sigbjornsdottir, B.I., Ragnarsson, G., Agnarsson, B.A. et al. Chromosome 8p alterations in sporadic and BRCA2 999del5 linked breast cancer. J Med Genet 2000, 37: 342-7.
63. Huiping, C., Sigurgeirsdottir, J.R., Jonasson, J.G. et al. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer. Br J Cancer 1999, 81: 1103-10.
64. Skirnisdottir, S., Eiriksdottir, G., Baldursson, T., Barkardottir, R.B., Egilsson, V., Ingvarsson, S. High frequency of allelic imbalance at chromosome region 16q22-q23 in human breast cancer: Correlation with high PgR and low S-phase. Int J Cancer 1995, 64: 112-6.
65. Berx, G., Cleton-Jansen, A.M., Strumane, K. et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancer by truncation mutations throughout its extracellular domain. Oncogene 1996, 13: 1919-25.
66. Lingle, W.L., Barrett, S.L., Negron, V.C. et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002, 99: 1978-83.
67. Sigurdsson, S., Bodvarsdottir, S.K., Anamthawat-Jonsson, K. et al. p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 2000, 121: 150-5.
68. Artandi, S.E. Complex roles for telomeres and telomerase in breast carcinogenesis. Breast Cancer Res 2003, 5: 37-41.
69. Artandi, S.E., Chang, S., Lee, S.L. et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406: 641-5.
70. O'Hagan, R.C., Chang, S., Maser, R.S., Mohan, R., Artandi, S.E., DePinho, R.A. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002, 2: 149-55.
71. Rennstam, K., Baldetorp, B., Kytola, S., Tanner, M., Isola, J. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 2001, 61: 1214-9.
72. Rummukainen, J.K., Salminen, T., Lundin, J., Joensuu, H., Isola, J. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 2001, 81: 1545-51.
73. Wu, K.-J., Grandori, C., Amacker, M. et al. Direct activation of TERT transcription by c-Myc. Nature Genet 1999, 21: 220-4.
74. Zhou, H.Y., Kuang, J., Zhong, L. et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nature Genet 1998, 20: 189-193.
75. Sen, S., Zhou, H.Y., White, R.A. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997, 14: 2195-200.
76. Miyoshi, Y., Iwao, K., Egawa, C., Noguchi, S. Association of centrosomal kinase STK15/ BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001, 92: 370-3.
77. Moody, S.E., Sarkisian, C.J., Hahn, K.T. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2: 451-61.
78. Gunther, E.J., Moody, S.E., Belka, G.K. et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003, 17: 488-501.
79. Chang, J.C., Woolen, E.G., Tsimelzon, A. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362: 362-9.